Abstract
The great success of targeted biologic therapy against rheumatoid arthritis (RA) in recent years has meant that much research has been devoted to investigating the pathophysiology of osteoarthritis (OA) in the hope of defining novel therapeutic targets. In contrast to RA, with its pannus and erosions, OA has long been thought of as a degenerative disease of cartilage, with secondary bony damage and osteophytes. But in recent years, the importance of the synovium, and in particular the synovial macrophages, in OA, has been highlighted in both in vitro and in vivo studies. This review will discuss the potential of synovial macrophages and their mediators, in particular the proinflammatory cytokines tumour necrosis factor α and interleukin-1, as potential therapeutic targets in OA.
Keywords: Aggrecanase, interleukin-1, matrix metalloproteinase, macrophage, osteoarthritis, synovium, tumour necrosis factor alpha
Current Drug Targets
Title: Activated Synovial Macrophages as Targets for Osteoarthritis Drug Therapy
Volume: 11 Issue: 5
Author(s): Jan Bondeson
Affiliation:
Keywords: Aggrecanase, interleukin-1, matrix metalloproteinase, macrophage, osteoarthritis, synovium, tumour necrosis factor alpha
Abstract: The great success of targeted biologic therapy against rheumatoid arthritis (RA) in recent years has meant that much research has been devoted to investigating the pathophysiology of osteoarthritis (OA) in the hope of defining novel therapeutic targets. In contrast to RA, with its pannus and erosions, OA has long been thought of as a degenerative disease of cartilage, with secondary bony damage and osteophytes. But in recent years, the importance of the synovium, and in particular the synovial macrophages, in OA, has been highlighted in both in vitro and in vivo studies. This review will discuss the potential of synovial macrophages and their mediators, in particular the proinflammatory cytokines tumour necrosis factor α and interleukin-1, as potential therapeutic targets in OA.
Export Options
About this article
Cite this article as:
Bondeson Jan, Activated Synovial Macrophages as Targets for Osteoarthritis Drug Therapy, Current Drug Targets 2010; 11 (5) . https://dx.doi.org/10.2174/138945010791011965
DOI https://dx.doi.org/10.2174/138945010791011965 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Important Anti-Cancer Applications of Protein Based Nanoparticles
Current Proteomics Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Current Pharmaceutical Design Dietary Supplement Use in Patients with Rheumatoid Arthritis in Japan
Current Rheumatology Reviews Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Cytokine Polymorphisms in Chronic Inflammatory Diseases with Reference to Occupational Diseases
Current Molecular Medicine Novel Therapeutic Targets for Somatostatin in Inflammatory Chronic Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A QSAR Study on a Series of Pyrrole Derivatives Acting as Lymphocyte- Specific Kinase (Lck) Inhibitors
Medicinal Chemistry Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives
Current Medicinal Chemistry CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets Novel, Acidic CCR2 Receptor Antagonists: From Hit to Lead
Letters in Drug Design & Discovery Withdrawal Notice: Electro-Catalytic process for the Synthesis of Organic Compounds and their Biological Applications
Current Organic Synthesis The Role of STATs in Inflammation and Inflammatory Diseases
Current Pharmaceutical Design Cytokines in the Pathogenesis of Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Design RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Biomedical Nano Tools: A Potential New Paradigm for Immunoassays and Immune Detection
Current Nanomedicine Association Study of IL-4 -590 C/T and DDX39B -22 G/C Polymorphisms with the Risk of Late-Onset Alzheimer’s Disease in Iranian Population
Current Aging Science Chemokines as Pharmacological Targets
Mini-Reviews in Medicinal Chemistry Changes in the Expression Profile of JAK/STAT Signaling Pathway Genes and Mirnas Regulating their Expression Under the Adalimumab Therapy
Current Pharmaceutical Biotechnology IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression
Current Drug Targets Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology